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the instruments’ Total Symptom Scores (TSS; item-scale correlations0.40). Inter-
nal consistency was strong (D-ABS TSS 0.92; D-MIQ Worries of Hypoglycemia
0.70; WN 0.90). Test-retest reliability was acceptable for both instruments
(D-ABS TSS ICC0.66; D-MIQ Worries of Hypoglycemia ICC0.65 WN ICC0.92).
CONCLUSIONS: The D-ABS and D-MIQ are psychometrically valid surveys for the
assessment of symptoms and impacts for T2DM. The surveys developed in this
study reduce the time required for the assessment of HS frequency and severity
(D-ABS), MC and MT, and weight impact (D-MIQ) in T2DM patients. The combina-
tion of psychometric validity and assessment time reduction make the D-ABS and
D-MIQ a viable means for in-trial and clinical assessment of HS and impacts.
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OBJECTIVES: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a novel class
of drugs to treat patients with Type 2 Diabetes Mellitus (T2DM). The attributes of
the SGLT2i differ from those of other medications. Therefore, patients’ preferences
for each of these attributes are of potential interest to patients, physicians, and
payers.METHODS:A discrete choice experiment was conducted with patients with
T2DM from the UK to examine 7 attributes of T2DM medications: efficacy (defined
as reduction in blood glucose levels), urinary tract infection/genital infection side-
effects, weight change, gastrointestinal/nausea side-effects, hypoglycemic events,
blood pressure, and cardiovascular risk. Patients were presented with 20 total
choices between 2 hypothetical T2DM medications each described by varying lev-
els of the 7 attributes. Partial utilities were estimated using random effects multi-
logit models, and relative importance (RI) values were calculated for each of the
attributes. Data were analyzed for the overall sample, and by medication and gen-
der subgroups. RESULTS: One hundred patients with T2DM completed the study
(51% male; mean age62.9, SD11.1 years; mean BMI32.7, SD6.5; 50.0% taking
2T2DM medications). The four most important attributes to patients were: risk of
hypoglycaemic events (relative importance (RI) 24.7%), weight change associated
with the medication (RI20.6%), risk of gastrointestinal/nausea side-effects
(RI18.6%), and efficacy (RI18.0%). The remaining attributes were of lesser impor-
tance: risk of urinary tract infection/genital infection side-effects (RI9.9%), car-
diovascular risk (RI4.3%), and blood pressure changes (RI3.9%). Additional re-
sults for subgroup analyses will be presented. CONCLUSIONS: Patients with T2DM
consider the risk of hypoglycaemic events, weight changes associated with a med-
ication, the risk of gastrointestinal/nausea side-effects, and the efficacy of a med-
ication to be attributes of approximately equivalent importance for T2DM medica-
tions. Prescribing physicians should consider these characteristics of medications
as they may contribute to patients’ overall satisfaction with their diabetes therapy.
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OBJECTIVES: Generic preference-based measures such as EQ-5D and SF-6D and
condition specific measures such as the Diabetes Health Profile-18 (DHP-18) are
used in the assessment of health related quality of life in diabetes. The aim of this
study was to investigate the psychometric acceptability, validity and responsive-
ness of these measures in a type 2 diabetes population. METHODS: Acceptability
was assessed by calculating missing data rates. We investigated the convergent
validity of the measures using correlations, known group validity across a variety
of clinical indicators using ANOVA, and agreement between the measures using
Intra Class Correlation coefficients (ICC) and Bland Altman plots. Responsiveness
to change over time was assessed using standardised response mean, and floor/
ceiling effect tests. A UK longitudinal sample of 1613 people with Type 2 diabetes
was used for the analysis.RESULTS:Overall rates of missing data were less than 5%
indicating acceptability to respondents. Across both time points, the DHP-18 di-
mensions were moderately correlated with the EQ-5D and SF-6D indicating con-
struct validity. All three measures significantly discriminated between those re-
porting and not reporting co-morbid health problems. In terms of agreement, the
ICC between the preference based measures was high, and Bland Altman plots
indicated that agreement is higher at the less severe end of the scale. The EQ-5D
displays evidence of a ceiling effect, and for patients self reporting change in
health, SRM statistics indicate that the sensitivity to change across time is low for
all measures.CONCLUSIONS:There is evidence for the psychometric validity of the
generic preference based measures EQ-5D and SF-6D and the condition specific
DHP-18 to measure outcomes in diabetes. However evidence for the responsive-
ness of the measures is less clear. The inclusion of both generic and condition
specific measures in trials may increase the accuracy of outcomes assessment in
type 2 diabetes.
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OBJECTIVES: Intensive glycemic control can increase the risk of hypoglycemia
among type 2 diabetes (T2D) patients, especially for people treated with insulin or
sulfonylureas. The goal of this study was to establish the content validity of a new
patient-reported outcome (PRO) instrument assessing multiple dimensions of the
patient’s experience of hypoglycemia – the Hypoglycemia Perspectives Question-
naire (HPQ). METHODS: The study included concept evaluation (to identify key
hypoglycemia perspectives to be assessed in the instrument), item generation, and
cognitive interviewing (to assess patient understanding of the HPQ) phases. The
concept evaluation phase included interviews with 19 T2D patients (mean age 
54.4, 37% male, 74% Caucasian) and 4 key opinion leaders, and a targeted review of
the literature. Two phases of cognitive interviews were conducted with T2D pa-
tients (Phase I: n6; Phase II: n5; 55% male, 45%  50 years old, 82% Caucasian);
changes to the HPQ were made in between phases. In concept elicitation and
cognitive interviews, respondents were interviewed one-on-one by a trained mod-
erator using a semi-structured interview guide. RESULTS: Key concepts emerging
from the concept evaluation phase included: frequency and severity of events,
emotional response to a hypoglycemia event, symptom concern, importance of
compensatory behaviors, personal control, worries, functional impact, and aware-
ness of symptoms. Tremor (79% of patients), dizziness (68%), and sweating (63%)
were the most commonly reported symptoms. Items were generated to assess the
key dimensions of hypoglycemia. The HPQ instructions, items, and response op-
tions were generally understood and only minor changes were made to the
instrument. CONCLUSIONS: The HPQ is a PRO instrument that can be used in
studies of T2D patients. It provides a comprehensive assessment of the patient’s
perspectives on hypoglycemia that goes beyond existing instruments. Once the
items are finalized via psychometric testing, the HPQ may be used to evaluate the
burden of hypoglycemia.
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OBJECTIVES: Fear for hypoglycemia has an impact on type 2 diabetes mellitus
(T2DM) patients’ Health-Related Quality of Life (HRQoL). The Worry Subscale of the
Hypoglycaemic Fear Survey-II (HFS-II) is a widely used tool. The objective is to test
the internal consistency, validity and reliability of a Spanish version of HFS-II for
determining the impact of fear for hypoglycemia on T2DM patients’ HRQL in Spain.
METHODS: Observational, cross-sectional, multicentre design. T2DM patients di-
agnosed from at least 1 year were recruited consecutively. Use of research tools:
1)Audit of Diabetes-Dependent Quality of Life/ADDQoL questionnaire [-9 to 9,
more negative scores indicate greater negative impact of diabetes on QoL];2)Worry
subscale of HFS-II [0-72, higher scores indicate increased fear];3)Visual Analogue
Scales (VAS) [0-10, higher scores indicate greater fear and impact of hypoglycemia].
For determining HSF-II internal consistency, validity and reliability, next parame-
ters were calculated: Cronbach’s alpha; ceiling/floor effects; correlations between
similar items scores of HFS-II/ADDQoL and between scores of two anchor ques-
tions (VAS) /HFS-II. RESULTS: A total of 3,812 patients (661 health care centers)
participated in the study [men (53.57%);mean(SD) age 63.70(11.37) years;mean(SD)
time from T2DM diagnosis 9.67(6.91) years]. 44.88% of patients referred at least one
episode of hypoglycemia in the previous six months. Mean(SD) HFS-II subscale
score was 24.41(17.05). It was higher in patients with hypoglycemia [31.32(15.71)]
compared to those without [18.85(16.03)](p0.0001). Cronbach’s alpha was 0.964. A
negative correlation was found between ADDQoL and HFS-II mean scores (-0.441;
p0.0001). Items that explore physical capacity, family, confidence, motivation,
future and dependence in ADDQoL and in HFS-II showed the highest correlations.
Anchorage questions’ (VAS) correlations (0.522-0.597) demonstrated an acceptable
face validity of the HFS-II individual items. Ceiling/floor effects below 20% suggest
its good functionality. CONCLUSIONS: These preliminary results show that the
HFS-II is consistent, valid and reliable for assessing fear for hypoglycemia in T2DM
patients in Spain.
PDB61
RESEARCH ON THE INCIDENCE AND COST OF HYPOGLYCEMIA EPISODE IN
PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
Zheng Y1, Wu J1, Österle A2
1Tianjin University, Tianjin, China, 2Vienna University of Economics and Business, Vienna,
Austria
OBJECTIVES: To know the incidence and cost of hypoglycemia episode in patients
with type 2 diabetes mellitus (T2DM) in China METHODS: A face-to face interview
was performed in 2 hospitals in Beijing and Tianjin with a well designed question-
naire. The incidence of mild, moderate and severe hypoglycemia as well as the
daily prevention cost and management cost per event were collected and investi-
gated in this study. RESULTS: The overall incidence of the study population was
54.04% within 1 year. A total 146 mild hypoglycemia episodes were reported in 79
patients within 1 week. A total 54 moderate hypoglycemia episodes were reported
in 37 patients within 1 month. A total 6 severe hypoglycemia episodes were re-
ported in 6 patients within 1 year. The well controlled (Fast Blood Glucose )FBG
group experienced the most mild hypoglycemia episodes and the group with treat-
ment of oral hypoglycemic agents combined with insulin had the highest hypogly-
cemia incidence within 1 year. The mean costs for mild, moderate and severe
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hypoglycemia were €0, €189 and €695 per event separately. CONCLUSIONS: Hypo-
glycemia is common acute side effect in treatment of T2DM patients, which asso-
ciated with considerable health and economic burden to patients and their family.
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OBJECTIVES: Although the prevalence of type 2 diabetes (T2D) is dramatically in-
creasing worldwide, data on the prevalence, prevalence of those at risk, and the
burden of these patients in Russia is lacking. METHODS: The data source for the
current study was the 2011 Russia National Health and Wellness Survey (NHWS), a
cross-sectional patient-reported health survey of adults in Russia (N10,039). Re-
spondents who reported a diagnosis of T2D were compared with non-T2D controls
on health status (measured using the SF-12v2), work productivity (measured using
the WPAI questionnaire), and number of resource use events using regression
modeling controlling for sociodemographic and health history variables. Among
respondents without a diagnosis of T2D, the prevalence and burden of key risk
factors were reported. RESULTS: A total of 288 respondents in Russia reported a
diagnosis of T2D (weighted prevalence: 2.77%). Among those not reporting a diag-
nosis, several risk factors were highly prevalent: 49.6% were overweight/obese,
17.5% had a family history of T2D, 34.5% currently smoke, 46.7% do not regularly
exercise, and 20.2% have hypertension. Patients with T2D were older (57.9 vs. 44.3),
had a lower annual income (19.1% vs. 11.2% had12,000 RUR), were more likely to
be obese (44.8% vs. 16.5%), and had a greater comorbidity burden (1.9 vs. 0.4) (all
p.05). Adjusting for group differences, patients with T2D reported significantly
worse physical health status (physical component summary scores: 43.46 vs. 46.25,
p.05). No significant differences were observed on work productivity or health
care resource use. CONCLUSIONS: The prevalence of T2D in Russia is modest but
may represent a large undiagnosed population, especially because the non-T2D
population reported a significant number of risk factors. The burden of T2D was
primarily observed through health status. Together, these results underscore the
importance of proper prevention and treatment of T2D.
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OBJECTIVES: Patients with acromegaly have significantly impaired health-related
quality of life (HRQOL). Results from a randomized, phase 3 study demonstrate
superior biochemical control for pasireotide LAR, a novel multireceptor somatosta-
tin analog, compared with octreotide LAR. The study also assessed patient-re-
ported HRQOL. METHODS: Medically naïve (after pituitary surgery or de novo)
patients with active acromegaly (GH level 5 g/L; elevated IGF-1) were random-
ized to receive pasireotide LAR 40mg (n176) or octreotide LAR 20mg (n182) in-
jections once every 28 days for 12 months. Biochemical control was defined as
GH2.5 g/L and normal IGF-1 at month 12. The AcroQoL questionnaire was used
to assess HRQOL. A change in AcroQoL total score of 9.8 was considered mean-
ingful based on a distribution-based estimate (1/2 standard deviation at baseline).
This analysis was conducted on patients with baseline and month 12 data (N275).
RESULTS: HRQoL improved from baseline to month 12 with both pasireotide LAR
(n132; mean [SD]  7.1 [14.7]) and octreotide LAR (n143; 5.1 [15.6]). Mean scores
were 58.5 and 55.9, respectively, at baseline and 65.3 and 61.5, respectively, at
month 12 for pasireotide LAR and octreotide LAR. These scores are consistent with
those previously reported for patients before and after effective treatment (56 [20];
65 [18]).1 Overall, 38.6% of pasireotide LAR patients met the AcroQoL criteria for a
clinically meaningful change vs. 34.3% of octreotide LAR patients. This pattern was
consistent for the AcroQoL physical and psychological subscales. For both treat-
ments at baseline and month 12, HRQOL was better in patients who achieved
biochemical control at month 12 (baseline: 62.9 [18.9] vs. 55.1 [19.5]); month 12: 66.9
[19.6] vs. 61.9 [22.0]). CONCLUSIONS: Pasireotide LAR treatment decreases GH and
IGF-1 and improves HRQOL. 1Webb et al, 2007.
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OBJECTIVES: To quantify patient preferences for outcomes associated with oral
type 2 diabetes mellitus (T2DM) treatments. METHODS: Adults in Sweden and
Germany with a self-reported physician diagnosis of T2DM and currently receiving
on oral anti-diabetic completed a web-enabled choice-format conjoint survey con-
sisting of a series of 9 choices between pairs of hypothetical medication profiles.
Each profile had different attributes within a pre-defined range, i.e., blood glucose
control (A1c), number of monthly mild-to-moderate hypoglycemic events (hypos) ,
one severe hypo per year (yes or no), weight gain per year, number of pills and
frequency of administration, and monthly cost to the patient. Choice questions
were based on an experimental design with known statistical properties. The sur-
vey was pretested with 25 patients using open-ended interviews. Bivariate probit
analysis was used to estimate probabilities for choosing how to take the medica-
tion based on patient characteristics and, conditional on that choice, preferences
for treatment outcomes. RESULTS:A total of 188 respondents in Sweden and 195 in
Germany completed the survey. Regarding the relative importance of the attributes
over the ranges included in both countries, weight gain was the most important
outcome followed by blood glucose control, for a once daily treatment. However,
avoiding a 5-kg weight gain was 1.5 times more important in Sweden and 2.3 times
more important in Germany than achieving moderate blood-glucose control. This
implies that blood glucose control was relatively more important to Swedish pa-
tients than German patients. Avoiding one severe hypo per year was the third most
important outcome in Sweden and fourth in Germany. In terms of the least impor-
tant outcome, it was number of pills taken once a day in Sweden and number of
monthly mild-to-moderate hypos in Germany. CONCLUSIONS: An oral T2DM
treatment that has no associated weight gain would be most preferred in both
Sweden and Germany.
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OBJECTIVES: An update of health economics analysis of type 2 diabetes mellitus
(T2DM) in adult population in Turkey was performed. The objectives of the analysis
were to determine the direct cost components caused by T2DM and its complica-
tions and also the loss of work productivity in T2DM. In this presentation, data on
work productivity are reported. METHODS: Forty centres were selected from the
list of centres in which adult T2DM patients were followed on a routine basis. These
centres were representative of the country, since they were selected by two-stage
cluster sampling. Data on work productivity were collected via “Work Productivity
and Activity Impairment Questionnaire: General Health V2.0 (WPAI:GH)”.
RESULTS: A total of 657 patients’ data were included in the analysis. The percent-
age of patients, who had a job, at the time of the study conducted, was 14.0%. This
figure was lower in patients with ophthalmic complications (8.7% vs. 15.9%;
p0.020) and with cardiovascular complications (4.1% vs. 15.7%; p0.002). Mean
scores of absenteeism, presenteeism and overall work productivity loss were
23.537.6%, 15.218.8%, and 38.637.8%, respectively. Overall impairment score of
work productivity was 22.725.0%. Patients with metabolic complications and
ophthalmic complications had reported more impairment (though non-signifi-
cant) (for metabolic complications 32.4% vs. 19.4%; p0.11; for ophthalmic compli-
cations 30.9% vs. 21.1%; p0.10). Overall impairment score of daily activities was
31.329.2%. Patients with metabolic complications and cardiovascular complica-
tions had reported more impairment (for metabolic complications 43.1% vs. 26.3%;
p0.001; and for cardiovascular complications 37.7% vs. 30.2%; p0.035).
CONCLUSIONS: DM is a disease that significantly impairs the opportunity to have
a job, and also impairs the work productivity and daily activities of patients. This
impairment is correlated with the presence of systemic complications. Thus, pre-
vention or effective treatment of complications in DM is crucial to improve the
social and economic consequences of the disease.
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OBJECTIVES: Cardiovascular disease is the major cause of death in patients with
type 2 diabetes (T2DM) and long-term follow-up from UKPDS showed improved
glycaemic control was associated with risk reduction for both myocardial infarc-
tion and death. The objective of this study was to quantify the expected difference
in long-term outcomes associated with blood glucose treated to target compared
with levels observed in clinical practice. METHODS: Data from UK primary care
(THIN) were used to obtain the demographic and risk factor profiles of patients
initiating monotherapy, dual therapy, and insulin-based therapy between 2005 and
2009. The Cardiff Type 2 Diabetes Model was initiated with cohort profiles consis-
tent with those subjects initiating monotherapy, and HbA1c change over time was
implemented under three scenarios: (1) HbA1c maintained at 6.5%; (2) therapy
escalation occurring at a threshold of 7.5%, and (3) therapy escalation occurring at
mean HbA1c levels observed in clinical practice. A 40-year time horizon using was
used with UK £ 2011 costs; both costs and benefits were discounted at 3.5%.
RESULTS:Data were available for 35,330 subjects; mean HbA1c (change) at therapy
initiation for mono, dual, and insulin therapy was 8.0% (-0.93%, p0.001), 8.5%
(-1.1%, p0.001), and 9.8% (-1.47%, p0.001), respectively. Under scenario 1, total
predicted costs (TC), life expectancy (LE), and quality-adjusted life-years (QALYs)
were £7,200, 16.4 years, and 13.7 QALYs, respectively. For scenario 2, TC, LE, and
QALYs were £14,416, 15.9 years, and 13.2 QALYs, respectively, whereas for scenario
3, TC increased to £14,914, while LE and QALYs decreased to 15.6 years and 12.8
QALYs, respectively. CONCLUSIONS: Failure to achieve glycaemic goals results in de-
creased life and quality adjusted life expectancy and excessive health care costs. Given
current budgetary constraints, an ageing population, and increasing obesity, it is impera-
tive that patients with T2DM are optimally managed in routine clinical practice.
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